Skip to main content

Key Product Details

Validated by

Biological Validation

Species Reactivity

Validated:

Human

Cited:

Human, Rat

Applications

Validated:

Flow (Cell Surface), Flow (Intracellular), Immunocytochemistry/ Immunofluorescence, Western Blot

Cited:

Flow (Cell Surface), Flow Cytometry Control, Immunocytochemistry/ Immunofluorescence, Western Blot

Label

Unconjugated

Antibody Source

Monoclonal Mouse IgG1 Clone # 186C426

Concentration

0.5 mg/ml

Product Specifications

Immunogen

This antibody was developed against KLH-conjugated synthetic peptide corresponding to amino acids 95-110 of human PGRP-1 beta.

Clonality

Monoclonal

Host

Mouse

Isotype

IgG1

Scientific Data Images for PGLYRP4/PGRP-I beta Antibody (186C426)

Western Blot: PGLYRP4/PGRP-I beta Antibody (186C426) [NB100-56721]

Western Blot: PGLYRP4/PGRP-I beta Antibody (186C426) [NB100-56721]

Western Blot: PGLYRP4/PGRP-I beta Antibody (186C426) [NB100-56721] - Analysis in cell lysates from human brain using a dilution of 2 ug/ml.
Immunocytochemistry/ Immunofluorescence: PGLYRP4/PGRP-I beta Antibody (186C426) [NB100-56721]

Immunocytochemistry/ Immunofluorescence: PGLYRP4/PGRP-I beta Antibody (186C426) [NB100-56721]

Immunocytochemistry/Immunofluorescence: PGLYRP4/PGRP-I beta Antibody (186C426) [NB100-56721] - A. HCECs were exposed to HKCA (106 cells/ml) with prior incubation in the absence or presence of isotype IgG (10ug/ml), dectin-1 neutralizing Ab (10ug/ml), BAY11-7082 (10uM) or NF-kB activation inhibitor quinazoline (NF-kB-I, 10uM) for 1 h. HCECs were treated with 106 cells/ml HKCA for 48 hours in 8-chamber slides and examined by immunofluorescent staining for PGLYRPs 3 (NB100-56729) and 4. C. The percentages of positive cells of PGLYRPs 3 and 4 staining in HCECs in A was quantified. Results shown are the mean +/- SD of four independent experiments; *** p<0.001, as compared with normal control; ^^ p<0.005, ^^^ p<0.001, as compared with HCECs exposed to HKCA. Magnification: 400x (bar = 25um). Image collected and cropped by CiteAb from the following publication (https://dx.plos.org/10.1371/journal.pone.0128039) licensed under a CC-BY license.
PGLYRP4/PGRP-I beta Antibody (186C426)

Immunohistochemistry: PGLYRP4/PGRP-I beta Antibody (186C426) [NB100-56721] -

Immunohistochemistry: PGLYRP4/PGRP-I beta Antibody (186C426) [NB100-56721] - NF-kappa B p65 activation was induced by HKCA & inhibited by dectin-1 neutralizing antibody & NF-kappa B activation inhibitor quinazoline (NF-kappa B-I) in HCECs.A. HCECs were exposed to HKCA (106 cells/ml) with prior incubation in the absence or presence of isotype IgG (10μg/ml), dectin-1 neutralizing Ab (10μg/ml), BAY11-7082 (10μM) or NF-kappa B activation inhibitor quinazoline (NF-kappa B-I, 10μM) for 1 h. HCECs were treated with 106 cells/ml HKCA for 48 hours in 8-chamber slides & examined by immunofluorescent staining for PGLYRPs 2–4. B. HCECs were treated for 4 hours in 8-chamber slides & were fixed in acetone for immunofluroscent staining total p65 (nuclear translocation) (green). C. The percentages of positive cells of PGLYRPs 2–4 staining in HCECs in A was quantified. D. The percentages of NF-ĸB p65 nuclear staining positive cells in B was quantified. Images are representatives from three independent experiments. Results shown are the mean ± SD of four independent experiments; *** p<0.001, as compared with normal control; ^^ p<0.005, ^^^ p<0.001, as compared with HCECs exposed to HKCA. Magnification: 400Х (bar = 25μm). Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/26039076), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Applications for PGLYRP4/PGRP-I beta Antibody (186C426)

Application
Recommended Usage

Flow (Cell Surface)

reported in scientific literature (PMID 15839897)

Flow (Intracellular)

reported in scientific literature (PMID 16849490)

Immunocytochemistry/ Immunofluorescence

1:10-1:2000. Use reported in scientific literature (Uehara et al (2005))

Formulation, Preparation, and Storage

Purification

Protein G purified

Formulation

PBS containing 0.0.5% BSA

Preservative

0.05% Sodium Azide

Concentration

0.5 mg/ml

Shipping

The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage

Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.

Background: PGLYRP4/PGRP-I beta

The primary immune recognition is based on structures common among invading pathogens. Bacterial surface molecules, such as lipopolysaccharide (LPS) and peptidoglycan (PGN), are known to elicit immune reactions ranging from cytokine release to fever. Recently, a family of proteins called peptidoglycan recognition protein (PGRP) has been identified in mouse and human that binds to peptidoglycans expressed on Gram-positive bacteria. Peptidoglycan (PGN) is an essential cell wall component of virtually all bacteria and, thus, it is an excellent target for recognition by the eukaryotic innate immune system. The PGRPs (PGRP-L, PGRP-S, PGRP-I alpha, and PGRP-I beta) define a new family of human pattern recognition molecules. PGRP-L is primarily expressed in the liver. Although liver is not considered a primary immune organ, liver participates in host defenses by producing acute phase proteins (by hepatocytes) in response to infections and by clearing microorganisms from blood.

Long Name

Peptidoglycan Recognition Protein Intermediate, Beta/Peptidoglycan Recognition Protein 4

Alternate Names

Pglyrp-1 beta, PGRP-I beta, PGRPI beta

Entrez Gene IDs

57115 (Human)

Gene Symbol

PGLYRP4

UniProt

Additional PGLYRP4/PGRP-I beta Products

Product Documents for PGLYRP4/PGRP-I beta Antibody (186C426)

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Product Specific Notices for PGLYRP4/PGRP-I beta Antibody (186C426)

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Loading...
Loading...
Loading...
Loading...
Loading...